TICKERNOMICS Sign up
Last Update: 2023-12-23 06:04:40
Ensysce Biosciences Inc. ( ENSC ) https://www.ensysce.com
1.06USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-87.73%
ENSC
SPY
30.72%
-99.97%
ENSC
SPY
112.82%
-99.95%
ENSC
SPY
201.04%
ENSC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3.27
2.16
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.35
1.04
2.83
-1105.49
0.00
-0.12
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-621.83
100.00
-589.38
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.6432
-2706.90
563.74
1.88
Other Earnings and Cash Flow Stats:
Ensysce Biosciences Inc. ( ENSC ) Net Income TTM ($MM) is -20.61
Ensysce Biosciences Inc. ( ENSC ) Operating Income TTM ($MM) is -17.63
Ensysce Biosciences Inc. ( ENSC ) Owners' Earnings Annual ($MM) is 0.00
Ensysce Biosciences Inc. ( ENSC ) Current Price to Owners' Earnings ratio is 0.00
Ensysce Biosciences Inc. ( ENSC ) EBITDA TTM ($MM) is -27.41
Ensysce Biosciences Inc. ( ENSC ) EBITDA Margin is -589.38%
Capital Allocation:
Ensysce Biosciences Inc. ( ENSC ) has paid 0.00 dividends per share and bought back -2.925146 million shares in the past 12 months
Ensysce Biosciences Inc. ( ENSC ) has reduced its debt by 16.212389 million USD in the last 12 months
Capital Structure:
Ensysce Biosciences Inc. ( ENSC ) Interest-bearing Debt ($MM) as of last quarter is 0
Ensysce Biosciences Inc. ( ENSC ) Annual Working Capital Investments ($MM) are -2
Ensysce Biosciences Inc. ( ENSC ) Book Value ($MM) as of last quarter is 1
Ensysce Biosciences Inc. ( ENSC ) Debt/Capital as of last quarter is 23%
Other Balance Sheet Stats:
Ensysce Biosciences Inc. ( ENSC ) has 1 million in cash on hand as of last quarter
Ensysce Biosciences Inc. ( ENSC ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Ensysce Biosciences Inc. ( ENSC ) has 3 common shares outstanding as of last quarter
Ensysce Biosciences Inc. ( ENSC ) has 0 million USD of preferred stock value
Academic Scores:
Ensysce Biosciences Inc. ( ENSC ) Altman Z-Score is -63.26 as of last quarter
Ensysce Biosciences Inc. ( ENSC ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Ensysce Biosciences Inc. ( ENSC ) largest shareholder is Vanguard Group Inc owning 15419 shares at 0.02 ($MM) value
Bob G Gower(an insider) Bought 7523 shares of Ensysce Biosciences Inc. ( ENSC ) for the amount of $44235.24 on 2023-03-02
5.70% of Ensysce Biosciences Inc. ( ENSC ) is held by insiders, and 9.90% is held by institutions
Ensysce Biosciences Inc. ( ENSC ) went public on 2018-02-26
Other Ensysce Biosciences Inc. ( ENSC ) financial metrics:
FCF:-15.89
Unlevered Free Cash Flow:0.00
EPS:-3.49
Operating Margin:-621.83
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-724.41
Beta:1.88
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Ensysce Biosciences Inc. ( ENSC ) :
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various preion drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.